Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention
出版年份 2016 全文链接
标题
Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 7, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2016-10-06
DOI
10.3389/fphar.2016.00356
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community
- (2016) Michael J. Hassett et al. BREAST CANCER RESEARCH AND TREATMENT
- Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer
- (2016) Hirofumi Matsumoto et al. BREAST CANCER RESEARCH AND TREATMENT
- Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer
- (2016) Yukiko Tabuchi et al. BREAST CANCER RESEARCH AND TREATMENT
- The immune system and hormone-receptor positive breast cancer: Is it really a dead end?
- (2016) Maria Vittoria Dieci et al. CANCER TREATMENT REVIEWS
- A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu–Expressing Tumor in HLA-A2 Transgenic Mice
- (2016) Thi Tran et al. CLINICAL CANCER RESEARCH
- Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice
- (2016) Stefanie N. Linch et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis
- (2016) Ke Wang et al. Oncotarget
- CD8+tumor-infiltrating lymphocytes contribute to spontaneous “healing” in HER2-positive ductal carcinoma in situ
- (2016) Michi Morita et al. Cancer Medicine
- Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
- (2016) Edith A. Perez et al. JAMA Oncology
- Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer
- (2016) Jashodeep Datta et al. JAMA Oncology
- T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells
- (2016) Prachi Namjoshi et al. Oncotarget
- Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial
- (2015) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Better Together: Targeted Combination Therapies in Breast Cancer
- (2015) Elisa Zanardi et al. SEMINARS IN ONCOLOGY
- Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration
- (2015) Tiziana Triulzi et al. Oncotarget
- CD4 + T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8 + T-cell Targeting of HER2/ neu –Expressing Cancers
- (2015) Jashodeep Datta et al. Cancer Immunology Research
- Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy
- (2015) Jashodeep Datta et al. Frontiers in Immunology
- Progressive loss of anti-HER2 CD4+T-helper type 1 response in breast tumorigenesis and the potential for immune restoration
- (2015) Jashodeep Datta et al. OncoImmunology
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- HER2-family signalling mechanisms, clinical implications and targeting in breast cancer
- (2014) N. Elster et al. BREAST CANCER RESEARCH AND TREATMENT
- CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful
- (2014) H.-J. Kim et al. Cancer Immunology Research
- Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest
- (2014) N. Acquavella et al. Cancer Immunology Research
- Antigen-Pulsed CpG-ODN-Activated Dendritic Cells Induce Host-Protective Immune Response by Regulating the T Regulatory Cell Functioning in Leishmania donovani-Infected Mice: Critical Role of CXCL10
- (2014) Saikat Majumder et al. Frontiers in Immunology
- Anti-HER2/Neu passive-aggressive immunotherapy
- (2014) Eric D Mortenson et al. OncoImmunology
- Circulating Type-1 Anti-Tumor CD4+T Cells are Preferentially Pro-Apoptotic in Cancer Patients
- (2014) Amy K. Wesa et al. Frontiers in Oncology
- Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer
- (2013) M. M. Kim et al. ANNALS OF ONCOLOGY
- Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice
- (2013) Yan Ge et al. CANCER LETTERS
- Advances and Future Directions in the Targeting of HER2-positive Breast Cancer: Implications for the Future
- (2013) Ishwaria M. Subbiah et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation
- (2013) Rodney A. Rosalia et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC
- (2013) Chandan Verma et al. Journal of Translational Medicine
- T-helper-1-cell cytokines drive cancer into senescence
- (2013) Heidi Braumüller et al. NATURE
- Inhibition of CD4+CD25+ Regulatory T Cell Function and Conversion into Th1-Like Effectors by a Toll-Like Receptor-Activated Dendritic Cell Vaccine
- (2013) Major K. Lee et al. PLoS One
- HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
- (2012) Anupama Sharma et al. CANCER
- Dendritic cell-based vaccines: barriers and opportunities
- (2012) Jessica A Cintolo et al. Future Oncology
- Targeting Stat3 Induces Senescence in Tumor Cells and Elicits Prophylactic and Therapeutic Immune Responses against Breast Cancer Growth Mediated by NK Cells and CD4+ T Cells
- (2012) M. Tkach et al. JOURNAL OF IMMUNOLOGY
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model
- (2012) Anamika Bose et al. MELANOMA RESEARCH
- The Promise of Antibody–Drug Conjugates
- (2012) Beverly A. Teicher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical trial results of the HER-2/neu(E75) vaccine to prevent breast cancer recurrence in high-risk patients
- (2011) Elizabeth A. Mittendorf et al. CANCER
- HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
- (2011) Devika Gajria et al. Expert Review of Anticancer Therapy
- The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology
- (2011) Suzanne A. Eccles INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
- (2011) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
- (2011) Sahar M.A. Mahmoud et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
- (2011) Jacalyn Rosenblatt et al. JOURNAL OF IMMUNOTHERAPY
- A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer
- (2011) Gary K. Koski et al. JOURNAL OF IMMUNOTHERAPY
- The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease
- (2011) Shuko Harada et al. JOURNAL OF SURGICAL ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation
- (2010) Kavya Rakhra et al. CANCER CELL
- CD4+ T-Cell Help in the Tumor Milieu Is Required for Recruitment and Cytolytic Function of CD8+ T Lymphocytes
- (2010) R. Bos et al. CANCER RESEARCH
- T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2
- (2010) Kousaku Mimura et al. INTERNATIONAL JOURNAL OF CANCER
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- The Role of Regulatory T Cells in Cancer
- (2010) Tai-You Ha Immune Network
- HER-2/neu Overexpression as a Predictor for the Transition from In situ to Invasive Breast Cancer
- (2009) R. E. Roses et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- Depletion of CD4+CD25+regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model
- (2009) H. Hong et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
- (2009) L. C. Benavides et al. CLINICAL CANCER RESEARCH
- Resistance to Trastuzumab in Breast Cancer
- (2009) P. R. Pohlmann et al. CLINICAL CANCER RESEARCH
- Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
- (2009) Mary L. Disis et al. JOURNAL OF CLINICAL ONCOLOGY
- The E75 HER2/neu peptide vaccine
- (2008) Elizabeth A. Mittendorf et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunological decision-making: how does the immune system decide to mount a helper T-cell response?
- (2007) Gerard E. Kaiko et al. IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started